What We're Reading: Page
Industry reads hand-picked by our editors
Jan 08, 2024
-
The Wall Street Journal
Boston Scientific To Acquire Axonics For About $3.7 Billion
-
Bloomberg Law
Sarepta Exes Out RegenxBio Patent in Delaware Federal Lawsuit
-
Retuers
Bayer’s menopausal relief drug succeeds in late-stage trial
-
Fierce Pharma
As CDMOs come off pandemic’s highs and lows, employment and funding hitches persist
Jan 05, 2024
Jan 04, 2024
-
Bloomberg
Bain Is Said to Explore €1 Billion Sale of Centrient Pharma
-
Reuters
CVS will remove AbbVie’s Humira from some drug reimbursement lists in April
-
FirstWord Pharma
Roche taps MOMA’s platform to develop novel cancer drugs
-
The Boston Globe
Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics
Jan 03, 2024
-
MIT Technology Review
We’ve never understood how hunger works. That might be about to change.
-
Reuters
Agios Pharma’s blood disorder drug meets goals of late-stage study
-
Science
Giant project will chart human immune diversity to improve drugs and vaccines
-
Bloomberg Law
FTC Gets Court Backing to Halt IQVIA’s Purchase of Propel Media
Jan 02, 2024
Dec 22, 2023
-
ApexOnco
A new order in BTK inhibition
-
Reuters
Jazz Pharmaceuticals’ PTSD drug fails in mid-stage trial
-
The Wall Street Journal
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
-
Fierce Biotech
AlloVir’s shares plunge 64% in wake of triple phase 3 disaster
Dec 21, 2023
-
The Philadelphia Inquirer
Merck’s diabetes drug highlights debate over U.S. patent system
-
Stat
Advocates call out ‘SNL’ over stereotypes, errors in sickle cell skit
-
BioSpace
Merck’s Chronic Cough Drug Fails to Secure FDA Approval for Second Time
-
The Wall Street Journal
Startup Fauna Bio Studies Animal Genomes for Clues to Human Diseases
Previous
